





Addressing Caregiver Burden and Identifying Agitation in Alzheimer's Dementia

 \odot 2024 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD

September 2024 US.CORP.D.24.00035

PsychU Webinar Rules Of Engagement

- Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) has entered into collaboration with OPEN MINDS, to explore new ways of bringing/increasing awareness around serious mental illness.
- OPDC's interaction with OPEN MINDS is through PsychU, an online, non-branded portal dedicated to providing information and resources on important disease state and care delivery topics related to mental illness. One of the methods employed for the sharing of information will be the hosting of webinars. Webinars conducted by OPDC are based on the following parameters:
- When conducting medical dialogue, whether by presentation or debate, OPDC and/or its paid consultants aim to provide the viewer with information that is accurate, not misleading, scientifically rigorous, and does not promote OPDC products. No continuing medical education (CME) credits are available for any PsychU program.
- OPDC and/or their paid consultants do not expect to be able to answer every question or comment during a PsychU webinar; however, they will do their best to address important topics and themes that arise.
- OPDC and/or their paid consultants are not able to provide clinical advice or answer questions relating to specific patient's condition.
- Otsuka employees and contractors should not participate in this program (e.g., submit questions or comments) unless they have received express approval to do so from Otsuka Legal Affairs.
- OPDC operate in a highly regulated and scrutinized industry. Therefore, we may not be able to discuss every issue or topic that you are interested in, but we will do our best to communicate openly and directly. The lack of response to certain questions or comments should not be taken as an agreement with the view posed or an admission of any kind.







This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Speakers are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc.

Our Featured Speaker



Lindsey Wright, PharmD Medical Science Liaison

Otsuka Pharmaceuticals Development & Commercialization, Inc. New Jersey



E. Jeffrey Greenberg, MD Neurologist at Princeton & Rutgers Neurology, P.A. Co-Founder of Advanced Clinical Institute New Jersey



Objectives

Define caregiver burden and its impact on daily life and ability to provide care to individuals with Alzheimer's dementia

Examine challenges in recognizing agitation in Alzheimer's dementia Share the Agitation in Alzheimer's Screener for Caregivers (AASC®) and the Caregiver's Guide on Identifying and Managing Agitation Associated with Alzheimer's Dementia resources



Alzheimer's dementia is highly prevalent and predicted to increase over time

An estimated

~6.9 MILLION ADULTS

age ≥65 years in the United States are currently living with **Alzheimer's disease**¹

By the year 2060, that number is expected **to double**, to ~13.8 MILLION ADULTS¹ **Agitation** is common in Alzheimer's dementia²



individuals with dementia due to Alzheimer's disease²



~65% of people with Alzheimer's or other forms of dementia live in the community, receiving more care from family members and other unpaid caregivers as their disease progresses¹


2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024;20(5):3708-3821.

2. Halpern R, et al. Int J Geriatr Psychiatry. 2019;34(3):420-431.



Agitation in Alzheimer's Dementia Displays a Broad Spectrum of Symptoms

- Agitation in Alzheimer's dementia is a common and treatable condition with a broad range of symptoms. It requires a treatment option distinct from those used for cognitive impairment¹⁻⁵
- Symptoms of agitation manifest as both non-aggressive and aggressive behaviors, such as^{6,7}:





7.

Rabinowitz J, et al. Am J Geriatr Psychiatry. 2005;13(11):991-998.

Agitation in Patients With Alzheimer's Dementia Has Been Associated With High Caregiver Burden Which Increases With Severity¹

AAD is a risk factor for burnout, reduced workability, and generally weaker health among caregivers²

Many professional caregiving themes parallel those	~						Uo
of family caregiving, ³ including caregiver outcomes ⁴⁻¹⁰ :	General health decline	Reduced quality of life	Depression	Anxiety	Embarrassment & guilt	Social isolation	Increased use of clinical services


AAD, agitation in Alzheimer's dementia.

- . Schein J, et al. J Alzheimers Dis. 2022;88(2):663-677.
- 2. Palm R, et al. J Alzheimers Dis. 2018;66(4):1463-1470.
- 3. McCarty EF and Drebing C. J Nurses Staff Dev. 2002;18(5):250-257.
- 4. Kales HC, et al. BMJ. 2015;350:h369.
- 5. Mohamed S, et al. Am J Geriatr Psychiatry. 2010;18(10):917-927.


- 6. Isik AT, et al. Int J Geriatr Psychiatry. 2019;34(9):1326-1334.
- 7. Brodaty H and Hadzi-Pavlovic D. Aust N ZJ Psychiatry. 1990;24(3):351-361.
- 8. Thomas P, et al. Int J Geriatr Psychiatry. 2006;21(1):50-56.
- 9. Patrick KS, et al. Psychogeriatrics. 2022;22(5):688-698.
- 10. Cohen-Mansfield J. J Psychiatr Res. 2008;43(1):64-69.
- The information provided by PsychU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Users seeking medical advice should consult with their physician or other health care professional.



Some Common Causes of Caregiver Burnout¹



American Medical Association. Caring for the caregiver: A guide for physicians. Caring for the Caregiver (ama-assn.org). Accessed on August 2024.





Current Approaches and Unmet Needs in Recognition of Agitation in Alzheimer's Dementia



- Are often the **first to encounter** agitation behaviors^{1,2}
 - **Do not recognize** the full breadth of agitation behaviors^{3,4}
 - Do not understand that treatment of agitation differs from treatment of Alzheimer's dementia⁵
 - Do not readily talk about agitation behaviors with HCPs^{3,6}



- HCPs often rely on caregivers to report agitation behaviors³:
 - Learn about agitation symptoms from caregivers
- Agitation symptoms may not be easy to detect in an office setting, especially when subtle



Early detection using the AASC® may⁷:

- Encourage discussions with HCPs about agitation symptoms
- Improve recognition and overall management of agitation in patients with Alzheimer's dementia
- Assist HCPs in making a diagnosis of agitation in Alzheimer's dementia


HCPs=healthcare providers.

- 1. Lindeza P, et al. BMJ Supportive & Palliative Care. 2024;14:e38-e49.
- 2. Gallego-Alberto L, et al. Clin Gerontol. 2022;45(5):1295-1303.
- 3. Stella F, et al. Int J Geriatr Psychiatry. 2015;30 (12):1230-123
- 4. Sano M, et al. Int Psychogeriatr. 2023:1-13.
- 5. Gilmore-Bykovskyi A, et al. Gerontologist. 2020;60(5):896-904.

- 6. Richler LG, et al. Harv Rev Psychiatry. 2023;31(1):22-27.
- 7. Clevenger C, et al. The Gerontological Society of America Annual Scientific Meeting; November 8-12, 2023; Tampa, FL
- The information provided by PsychU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Users seeking medical advice should consult with their physician or other health care professional.



The AASC® was created with caregiver feedback along with agitation in Alzheimer's dementia clinical experts and a patient representative



The AASC[®] Website: https://theaasc.com/







A Resource for Caregivers

Agitation in Alzheimer's Screener for Caregivers (AASC) Brochure & A Caregiver's Guide: Identifying and Managing Agitation Associated with Alzheimer's Dementia





Closing



Get Your Resources On The Go





Download the PsychU App from Google Play or from the Apple App Store!



app.

Subscribe to The PsychU Community Podcast on the Google Podcasts app or on the Apple Podcasts

Connect with us on social media:











Addressing Caregiver Burden and Identifying Agitation in Alzheimer's Dementia

 \odot 2024 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD

September 2024 US.CORP.D.24.00035